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Abstract
Background Low muscle mass occurs in patients with rheumatoid arthritis without weight loss; this condition is referred as
rheumatoid cachexia. The aim of the current study was to perform a systematic review with meta-analysis to determine the
rheumatoid cachexia prevalence.
Methods A systematic review with meta-analysis of observational studies published in English, between 1994 and 2016, was
conducted using MEDLINE (via PubMed) and other relevant sources. Search strategies were based on pre-defined keywords
and medical subject headings. The methodological quality of included studies was assessed using the Newcastle-Ottawa Scale.
Meta-analysis was used to estimate the prevalence, and because studies reported different methods and criteria to estimate
body composition and prevalence of rheumatoid cachexia, subgroup analyses were performed. Meta-regression adjusted for
the 28-joint disease activity score and disease duration (years) was performed (significance level at P ≤ 0.05).
Results Of 136 full articles (one duplicate publication) screened for inclusion in the study, eight were included. The esti-
mated overall prevalence of rheumatoid cachexia was 19% [95% confidence interval (CI) 07–33%]. This prevalence was 29%
(95% CI 15–46%) when body composition was measured by dual-energy X-ray absorptiometry. When the diagnostic criteria
were fat-free mass index below the 10th percentile and fat mass index above the 25th percentile, rheumatoid cachexia prev-
alence was 32% (95% CI 14–52%). The 28-joint disease activity score and disease duration had no influence on the estimated
prevalence of rheumatoid cachexia (P > 0.05). Most studies were rated as having moderate methodological quality.
Conclusions Meta-analysis showed a prevalence of rheumatoid cachexia of 15-32%, according to different criteria, demon-
strating that this condition is a frequent comorbidity of rheumatoid arthritis. To better understand its clinical impact, more
studies using standardized definitions and prospective evaluations are urgently needed.
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Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory autoim-
mune disease characterized by chronic, symmetric, and erosive
synovitis that may lead to severe disability and premature
death.1–3 In addition to joint damage, changes in body compo-
sition have been observed in patients with RA, including
reduced fat-freemass (FFM), ofwhichmusclemass is themajor
component, with or without loss of fat mass (FM), resulting in
no or limited changes in body mass index.4,5 This condition
has been referred to as rheumatoid cachexia (RC).6–8
The definition of ‘cachexia’ (classic cachexia), ‘sarcopenia’,
‘sarcopenic obesity’, and ‘RC’ is diverse in the available litera-
ture. Sarcopenia (Greek ‘sarx’ or flesh and ‘penia’ or loss) is
currently used to characterize the combination of low muscle
mass and function (strength and performance),9,10 while
sarcopenic obesity refers to the copresence of both sarcopenia
and obesity. Classic cachexia (Greek ‘kako’s’ or bad and ‘he’xis’
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or condition) is a term used to characterize the condition in-
volving severe loss of weight, fat, and muscle mass and in-
creased protein catabolism due to underlying disease(s).11,12
Roubenoff et al.5,13 described a common reduction in total
body cell mass (BCM) in patients with RA and referred to this
condition as RC. BCM consists primarily of muscle mass, with
visceralmass (serumproteins, erythrocytes, granulocytes, lym-
phocytes, liver, kidneys, pancreas, and heart) and immune cell
mass contributing lesser amounts. Also, this author considers
FM, extracellular water, connective tissue (cartilage, fibrous
tissues, and skeletal tissues), and bone, components not in-
cluded in BCM. However, recently, Engvall et al. described RC
as adverse changes in body composition (reduced FFM with
or without loss of FM) in patients with RA.14,15
Excess of pro-inflammatory cytokines as IL-1 beta and TNF-
alpha is considered to be the central feature in RC.5 In addition,
as for clinical outcomes, RC has been associated with an in-
creased risk of physical disability, morbidity, andmortality.16,17
Despite several publications on RC, there is no consensus
on the clinical criteria for its diagnosis,18 leading to consider-
able variability in reports of RC prevalence. Attempts have
been made to diagnose RC based on body composition mea-
sured by different methods, including computed tomography,
magnetic resonance imaging, dual-energy X-ray absorptiome-
try (DEXA), bioelectrical impedance analysis (BIA), and an-
thropometric methods. In addition to different methods to
evaluate body composition, different criteria have been used
to diagnose RC.11,14,19 Therefore, the diagnostic criteria used
for RC and the method used to measure body composition
can greatly impact the estimation of RC prevalence, but this
has not been systematically studied. The aim of the current
study was to systematically review the literature and esti-
mate the RC prevalence.
Methods
We conducted this systematic review with meta-analysis in
accordance with PRISMA guidelines20 after registering the
protocol with PROSPERO (CRD42017073495).
Data sources
An electronic search was performed using MEDLINE (via
PubMed) and other relevant sources. We used a comprehen-
sive search strategy tailored to each database.
Search terms
Keywords and medical subject headings for the terms ‘rheu-
matoid arthritis’, ‘arthritis’, ‘arthritis rheumatoid’ AND
‘cachexia’ AND ‘sarcopenia’ were selected.
Inclusion/exclusion criteria
Cross-sectional and cohort studies were included in the sys-
tematic review and meta-analysis. Studies on experimental
models, randomized controlled trials, and reviews; studies
on other diseases or topics; and studies without prevalence
data of RC were excluded. In addition, studies that evaluated
only muscle mass, without providing data on FM, were
excluded.
Data extraction
Title, abstract, and full-text screening were performed in du-
plicate by two independent reviewers (Santo, R. C. E. and
Fernandes, K. Z.). The reviewers independently extracted
data from the studies using a pre-established data extraction
form, which is available upon request. All study data were re-
corded using a bibliographic management program
(Mendeley®, version 1.17.9). Disagreements about data
abstraction were resolved by discussion between the two re-
viewers. If no agreement could be reached, a third and fourth
reviewers (Filippin, L. and Lora, P.) provided the final deci-
sion. Information extracted during data abstraction included
author names, date of publication, journal of publication,
number of study participants, age range of population, type
of population, definition of RC [with method(s) of body
composition assessment, cut-off points, and reference popu-
lation], and RC prevalence (percentage or number of partici-
pants with and without RC).
Strategy for data synthesis
The Newcastle-Ottawa Scale, adapted for cross-sectional
studies, was used to assess methodological quality of sam-
pling, selection, exposure, and clinical outcomes of the stud-
ies selected. Using the Newcastle-Ottawa Scale, each study
was judged on seven items categorized into three groups: se-
lection of study groups; comparability of groups; and ascer-
tainment of either the exposure or outcome of interest. The
maximum possible score was 10 stars, which represented
the highest methodological quality.21 Studies awarded 7–10
stars were rated as having high quality; 5–6 stars, as having
moderate quality; and <5 stars, as having low quality.22 Stud-
ies include independently of the methodological quality cal-
culated. Meta-analysis was performed using Stata® 11.0.
The prevalence of RC [with 95% confidence intervals (CI)]
was estimated using random effect adjust and Freeman–
Tukey double arcsine transformation (FFT). The I2 statistic
was used to assess heterogeneity among studies. Meta-
regression adjusted for the 28-joint disease activity score
(DAS28) and disease duration (years) was performed, and
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the significance level was set P ≤ 0.05. All analyses were per-
formed using the metaprop command in Stata.
Results
Search strategy
We identified 136 potentially relevant full articles (one dupli-
cate publication) based on the search strategy described at
the initial search stage. Figure 1 shows the flow diagram of
study selection. After title, abstract, and full-text screening,
127 articles were excluded (25 experimental model; 40 re-
views; 10 clinical trials; 10 other populations; 26 other topics;
and 16 without prevalence of RC) in accordance with
inclusion/exclusion criteria. Therefore, eight relevant full arti-
cles were included in the review and incorporated into the
meta-analysis.
Characteristics of the studies
All included studies were published between 2008 and 2016.
Sample sizes ranged from 50 to 400 patients, with a female
predominance. Mean age ranged from 54.1 to 65.0 years.
DAS28 ranged from 3.1 to 5.2. The characteristics of the
included studies are summarized in Table 1. All studies had
a cross-sectional design. Most studies were conducted in
European populations, while one was from Morocco, and
another was from South Africa.
Diagnostic criteria for rheumatoid cachexia
Most studies used only body composition parameters as diag-
nostic criteria for RC. Fat-free mass index (FFMI) below the
10th percentile and fat mass index (FMI) above the 25th
percentile, as proposed by Engvall et al.,14 were used as
diagnostic criteria for RC in six (75.0%) of eight included
studies.14,19,23–28 Of the remaining two studies, one used
the diagnostic criteria proposed by Elkan et al. of FFMI below
the 25th percentile and FMI above the 50th percentile,19 and
the other used the diagnostic criteria proposed by Evans
et al. that includes another parameters besides body compo-
sition {body weight loss of 5% or more within 12 months [or a
body mass index ≤20 kg/m2] and at least three of the follow-
ing factors: decreased muscle strength; fatigue; anorexia; low
FMI; and abnormal biochemistry [increased inflammatory
Figure 1 Flow diagram of search results and study selection.
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markers (CRP, IL-6), anaemia (Hb <12 g/dL), low serum
albumin (<3.2 g/dL)]}.11
Methods of body composition assessment for
rheumatoid cachexia
Of eight included articles, five (62.5%) used total-body DEXA,
two (25.0%) used BIA,23,25 and one (12.5%) used anthropo-
metric measurements.26
Rheumatoid cachexia prevalence
Rheumatoid cachexia prevalence ranged from 1.0% to 53.9%
(Table 1). El Maghraoui et al.27 found the highest prevalence
using the diagnostic criteria for RC proposed by Engvall
et al.,14 while Bokhorst et al.25 found the lowest prevalence
using the diagnostic criteria for cachexia proposed by Evans
et al.11
Meta-analysis
In the overall meta-analysis (body composition as the only cri-
terion), RC prevalence estimated was 19% (95% CI 07–33%)
with I2 = 96.74%, P = 0.00 (Figure 2). Two subgroup analyses
were performed.When body composition determine by DEXA,
RC prevalence was estimated at 29% (95% CI 15–46%) with
I2 = 92.63%, P = 0.00 (Figure 3), and when FFMI below the
10th percentile and FMI above the 25th percentile were used
as diagnostic criteria, RC prevalence estimated was 32% (95%
CI 14–52%) with I2 = 93.24%, P = 0.00 (Figure 4). In the meta-
regression model, neither DAS28 nor age had an influence
on the RC estimated prevalence (P = 0.545, SEM = 0.04; and
P = 0.614, SEM = 0.02, respectively).
This prevalence was when body composition was mea-
sured by DEXA.
Methodological quality of the studies
The methodological quality of included studies is described in
Table 2. Most studies were rated as having moderate quality.
Discussion
Rheumatoid cachexia is a term used to characterize adverse
changes in body composition that involve reduction in FFM
and maintenance or increase in FM in patients with RA. These
Figure 2 Forest plot of the prevalence of rheumatoid cachexia using body composition (assessed by dual-energy X-ray absorptiometry, bioelectrical
impedance analysis, or anthropometric measurements) as a diagnostic criterion; ES, estimated; I^2, heterogeneity among studies.
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Figure 3 Forest plot of the prevalence of rheumatoid cachexia using dual-energy X-ray absorptiometry. ES, estimated; I^2, heterogeneity among
studies.
Figure 4 Forest plot of the prevalence of rheumatoid cachexia using dual-energy X-ray absorptiometry and fat-free mass index below the 10th per-
centile and fat mass index above the 25th percentile as diagnostic criteria. ES, estimated; I^2, heterogeneity among studies.
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changes may be related to pro-inflammatory cytokine-
induced hypermetabolism.13–15 To our knowledge, this is
the first systematic review with meta-analysis to estimate
the prevalence of RC in patients with RA. Of the eight articles
included in our study, seven studies used diagnostic criteria
developed specifically for RC—six used the criteria proposed
by Engvall et al.,14 and one used the criteria proposed by
Elkan et al.,19 while one study used the criteria for classic
cachexia proposed by Evans et al.11
The estimated RC prevalence was 19% (95% CI 07–33%).
However, estimated prevalence varied when studies with
different methods of body composition assessment or
different cut-off points were included in the analysis. In the
analysis using specific diagnostic criteria for RC and DEXA,
the estimated prevalence of RC was 29%. Nevertheless, in
the analysis using specific criteria for RC, DEXA, and the cut-
off points proposed by Engvall et al.14 (i.e. FFMI below
the 10th percentile and FMI above the 25th percentile), the
estimated prevalence of RC was 32% (95% CI 14–52%). There-
fore, we can state that RC is influenced by the method of
body composition assessment and criteria used for diagnosis.
Body composition analysis refers to the quantification of
the main structural components of the human body, divided
into specific tissues that compose the total body mass.29,30
Methods of body composition assessment such as DEXA,
BIA, and anthropometric measurements have been used in
the clinical and research settings. Using BIA, Bokhorst
et al.25 found a very low prevalence of RC (1%). Metsios
et al.,23 also using BIA, found a prevalence of RC of 8.5%.
Elkan et al.24 compared BIA and DEXA and found good agree-
ment between the two methods, but BIA showed higher lean
mass values and lower FM values. Although BIA has lower
cost, greater ease of use, and higher measurement speed,
the use of this technique requires that the person undergo
a set of previous procedures, without which there may be
loss of information quality obtained from FM when
compared with DEXA.
In addition to these precautions, equipment characteristics
and calibration, body position, individual hydration level and
food intake, ambient and cutaneous temperature, and use of
heavier garments and metal parts may have some influence
on the quality of measurements.31,32 Using anthropometric
measurements to assess body composition in patients with
RA, Lombard et al.26 found a prevalence of RC of 10.3%.
Anthropometric measurement is considered a double indirect
method of body composition assessment, and the instru-
ments used, the evaluator’s ability, intra-rater and inter-rater
errors, individual factors (hydration level, physical exercise,
and menstrual cycle), and the choice of the anthropometric
prediction equation, among other factors, may be a source
of error.33–36
Using DEXA as the method of body composition assess-
ment in patients with RA, Hugo et al.28 found an RC preva-
lence of 18%, while El Maghraoui et al.27 found a
prevalence of 53.9%. A number of techniques are being used
to assess body composition as water dilution, anthropometry,
DEXA, analysis of computerized tomography and magnetic
resonance imaging, and BIA.37 However, DEXA represents a
reliable alternative method, non-invasive, improved feasibil-
ity, lower cost, minimal radiation exposure, high accuracy,
sensitive and reproducibility for measuring FM and
FFM.38,39 In addition, DEXA is a clinically accessible method
that is widely used in bone mineral density measurement
for the evaluation of osteoporosis; therefore, it is also
suitable for the analysis of body composition.
Rheumatoid cachexia prevalence also varied according to
the criteria used for diagnosis, because the diagnostic criteria
for RC are not well established. Engvall et al.14 and Elkan
et al.19 proposed a RC diagnostic criteria that include changes
in FFM and FM. Engvall et al.14 used data from a Swiss popu-
lation sample of healthy adults (2986 men and 2649 women)
to found body composition index that determine RC. There-
fore, RC was classified as FFMI below the 10th percentile
and FMI below the 25th percentile. Using these cut-off
points, they found an RC prevalence of 38%. Other studies
conducted using the same diagnostic criteria (and cut-off
points) found an RC prevalence ranged from 8.5% to 53.9%.
Elkan et al.19 proposed a variation in the same parameters
but different cut-off point and the same Swiss population da-
tabase used by Engvall et al.14 for RC in order to test the as-
sociation of RC with dyslipidaemia and risk of cardiovascular
disease. Patients with RA were classified as having RC if they
Table 2 Description of quality assessment using the Newcastle-Ottawa Scale (NOS)









Hugo et al.28 France ** * ** 5
El Maghraoui et al.27 Morocco ** * ** 5
Lombard et al.26 South Africa **** * ** 7
Bokhorst et al.25 Netherlands ** * 3
Elkan et al.24 Sweden ** * ** 5
Elkan et al.19 Sweden ** * ** 5
Metsios et al.23 UK ** * *** 6
Engvall et al.14 Sweden ** * ** 5
Asterisks (*) Represents the number of “stars” of quality Newcastle-Ottawa Scale (NOS).
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had FFMI below the 25th percentile and FMI above the 50th
percentile.19 Using these cut-off points, they found an RC
prevalence of 21% for women and 26% for men. Despite
the difference between the RC criteria proposed by Engvall
et al.14 and by Elkan et al.,19 no apparent difference was
observed between prevalence rates.
Evans et al.,11 however, proposed a diagnosis of cachexia
to be used in several diseases, including RA. Based on these
criteria, Bokhorst et al.25 found a prevalence of RC of 1%.
Physical inactivity40 and treatment effects,41–43 due to the ef-
fective reversal of the systemic inflammatory process, seem
to affect the gain or maintenance of body weight in patients
with RA. Therefore, patients with controlled RA do not lose
body weight, and, for this reason, the prevalence of RC using
the diagnostic criteria proposed by Evans et al.11 is lower
than that reported in the studies that used the diagnostic
criteria proposed by Engvall et al.14 or by Elkan et al.19,24
In fact, no study evaluated the impact of RC on patient out-
comes, and no study prospectively validated these criteria. To
define the best criterion, such studies are required. Despite
the lack of body weight loss, patients with RA lose muscle
mass compared with healthy individuals. Loss of muscle
mass is commonly evaluated in classic cachexia, RC, and
sarcopenia; therefore, these syndromes are often confused
with one another.
Using loss of muscle mass as a diagnostic criterion for
sarcopenia in patients with RA, studies have reported preva-
lence rates of sarcopenic patients ranging from 11.0% to
57.1%. However, studies that evaluated only loss of muscle
mass were not included in our systematic review with
meta-analysis, because the objective was to specifically eval-
uate RC according to currently used RC diagnostic criteria.
Considering that patients with RA have a decrease in lean
mass, maintenance or increase in adipose tissue, and changes
in functionality, Weber et al.44,45 proposed a new parameter
of adiposity-adjusted muscle mass (ALMIFMI). This parameter
was defined as appendicular lean mass divided by height
squared adjusted for age and body fat (adjZ-score), and low
lean mass was defined as adjZ-score less than 1.0, leading
to stronger positive associations with functional results com-
pared with unadjusted estimates in patients with RA.44,45
Thus, it is suggested that this new parameter be used in fu-
ture sarcopenia and cachexia studies of patients with RA.
The systemic inflammatory process of RA has been associ-
ated with altered body composition and RC.14 Elkan et al.
assessed patients with mild to moderate disease activity
and found an RC prevalence of 18.0%19,24 for women and
21.024–26.0%19 for men. Conversely, studies evaluating
patients with moderate to high disease activity found an RC
prevalence of 18–53.9%.14,19,24,27,28 In our meta-analysis, no
association between disease activity and RC was demon-
strated, probably because most patients had moderate to
high disease activity (DAS28 between 3.1 and 5.2) and be-
cause all studies had a cross-sectional design, thereby
preventing the evaluation of changes in body composition
and disease activity over time.
Regardless of whether there is agreement between the di-
agnostic criteria and methods used for body composition as-
sessment, there is common agreement that RC affects the
clinical outcome of patients. Patients with RA have increased
IL-6 and TNF within the muscle. These muscle inflammatory
markers correlate with physical inactivity and disability.46
Engvall et al.14 demonstrated that patients with RA who
had RC and high disease activity had lower physical activity
and IGF-1 levels. In addition to muscle alterations, patients
with RA also have endothelial dysfunction and increased risk
of atherosclerosis and cardiovascular disease.47–49 However,
the effects of RC on the risk of cardiovascular disease are still
controversial.50 Elkan et al.,19 in patients with RA who had RC
and moderate disease activity, found high levels of total cho-
lesterol and low-density lipoprotein, low levels of IgM against
phosphorylcholine (anti-PC IgM), and high frequency of hy-
pertension. However, in patients with RA and moderate RC,
disease activity does not appear to be associated with worse
cardiovascular disease profile23 or metabolic syndrome.28
Impaired bone metabolism may also be present, because pa-
tients with RA and RC have lower hip bone mineral density
than patients without RC.27 Considering that RC affects the
clinical outcome of patients, longitudinal studies are needed
to fill the gaps in the literature regarding the effects of RC
on patients with RA.
The main limitation of this study is the small number of RC
studies included, making meaningful meta-analysis difficult.
In conclusion, the results of this systematic review with
meta-analysis indicate that the estimated prevalence of RC
ranges from 19% to 32% and that there is variability in the
prevalence rates according to the diagnostic criteria used
for RC. Therefore, there is a need for greater standardization
of terms such as RC, cachexia, and sarcopenia, as well as for
further prospective studies aiming to clarify the impact of this
comorbidity on clinical outcomes.
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